Table 2.
Incidence of Most Frequent Treatment-Related Adverse Events
| Event | Patients by Event Grade (N = 47) |
|||||||
|---|---|---|---|---|---|---|---|---|
| Grade 1 |
Grade 2 |
Grade 3 |
Grade 4 |
|||||
| No. | % | No. | % | No. | % | No. | % | |
| Nausea | 3 | 6 | 2 | 4 | 2 | 4 | 0 | |
| Constipation | 1 | 2 | 4 | 9 | 0 | 0 | ||
| Fatigue | 2 | 4 | 10 | 21 | 3 | 6 | 0 | |
| Peripheral edema | 2 | 4 | 5 | 11 | 0 | 0 | ||
| Hypokalaemia | 25 | 53 | 0 | 1 | 2 | 0 | ||
| Anorexia | 4 | 9 | 4 | 9 | 1 | 2 | 0 | |
| Hyperglycemia | 1 | 2 | 5 | 11 | 0 | 0 | ||
| Headache | 3 | 6 | 2 | 4 | 0 | 0 | ||
| Hypertension | 3 | 6 | 5 | 11 | 0 | 0 | ||
NOTE. Treatment-related effects from abiraterone acetate or steroid treatment. Only events occurring in ≥ 10% of patients are reported in this Table. One patient reported grade 4 increase in transaminases not shown in the Table.